Literature DB >> 19221438

Astrocyte elevated gene-1 regulates hepatocellular carcinoma development and progression.

Byoung Kwon Yoo1, Luni Emdad, Zao-zhong Su, Augusto Villanueva, Derek Y Chiang, Nitai D Mukhopadhyay, Alan Scott Mills, Samuel Waxman, Robert A Fisher, Josep M Llovet, Paul B Fisher, Devanand Sarkar.   

Abstract

Hepatocellular carcinoma (HCC) is a highly aggressive vascular cancer characterized by diverse etiology, activation of multiple signal transduction pathways, and various gene mutations. Here, we have determined a specific role for astrocyte elevated gene-1 (AEG1) in HCC pathogenesis. Expression of AEG1 was extremely low in human hepatocytes, but its levels were significantly increased in human HCC. Stable overexpression of AEG1 converted nontumorigenic human HCC cells into highly aggressive vascular tumors, and inhibition of AEG1 abrogated tumorigenesis by aggressive HCC cells in a xenograft model of nude mice. In human HCC, AEG1 overexpression was associated with elevated copy numbers. Microarray analysis revealed that AEG1 modulated the expression of genes associated with invasion, metastasis, chemoresistance, angiogenesis, and senescence. AEG1 also was found to activate Wnt/beta-catenin signaling via ERK42/44 activation and upregulated lymphoid-enhancing factor 1/T cell factor 1 (LEF1/TCF1), the ultimate executor of the Wnt pathway, important for HCC progression. Inhibition studies further demonstrated that activation of Wnt signaling played a key role in mediating AEG1 function. AEG1 also activated the NF-kappaB pathway, which may play a role in the chronic inflammatory changes preceding HCC development. These data indicate that AEG1 plays a central role in regulating diverse aspects of HCC pathogenesis. Targeted inhibition of AEG1 might lead to the shutdown of key elemental characteristics of HCC and could lead to an effective therapeutic strategy for HCC.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19221438      PMCID: PMC2648696          DOI: 10.1172/JCI36460

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  79 in total

1.  Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma.

Authors:  Andrew X Zhu; Lawrence S Blaszkowsky; David P Ryan; Jeffrey W Clark; Alona Muzikansky; Kerry Horgan; Susan Sheehan; Kelly E Hale; Peter C Enzinger; Pankaj Bhargava; Keith Stuart
Journal:  J Clin Oncol       Date:  2006-04-20       Impact factor: 44.544

Review 2.  Pyruvate kinase type M2 and its role in tumor growth and spreading.

Authors:  Sybille Mazurek; C Bruce Boschek; Ferdinand Hugo; Erich Eigenbrodt
Journal:  Semin Cancer Biol       Date:  2005-08       Impact factor: 15.707

3.  The role of thymidylate synthase and dihydropyrimidine dehydrogenase in resistance to 5-fluorouracil in human lung cancer cells.

Authors:  Tetsuya Oguri; Hiroyuki Achiwa; Yuji Bessho; Hideki Muramatsu; Hiroyoshi Maeda; Takashi Niimi; Shigeki Sato; Ryuzo Ueda
Journal:  Lung Cancer       Date:  2005-09       Impact factor: 5.705

4.  Cloning and characterization of HIV-1-inducible astrocyte elevated gene-1, AEG-1.

Authors:  Dong-Chul Kang; Zao-Zhong Su; Devanand Sarkar; Luni Emdad; David J Volsky; Paul B Fisher
Journal:  Gene       Date:  2005-06-20       Impact factor: 3.688

5.  Complete pathological remission is possible with systemic combination chemotherapy for inoperable hepatocellular carcinoma.

Authors:  T W Leung; Y Z Patt; W Y Lau; S K Ho; S C Yu; A T Chan; T S Mok; W Yeo; C T Liew; N W Leung; A M Tang; P J Johnson
Journal:  Clin Cancer Res       Date:  1999-07       Impact factor: 12.531

6.  Activation of the nuclear factor kappaB pathway by astrocyte elevated gene-1: implications for tumor progression and metastasis.

Authors:  Luni Emdad; Devanand Sarkar; Zao-zhong Su; Aaron Randolph; Habib Boukerche; Kristoffer Valerie; Paul B Fisher
Journal:  Cancer Res       Date:  2006-02-01       Impact factor: 12.701

7.  Liver-targeted disruption of Apc in mice activates beta-catenin signaling and leads to hepatocellular carcinomas.

Authors:  S Colnot; T Decaens; M Niwa-Kawakita; C Godard; G Hamard; A Kahn; M Giovannini; C Perret
Journal:  Proc Natl Acad Sci U S A       Date:  2004-11-24       Impact factor: 11.205

8.  A randomized phase III study of doxorubicin versus cisplatin/interferon alpha-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma.

Authors:  Winnie Yeo; Tony S Mok; Benny Zee; Thomas W T Leung; Paul B S Lai; Wan Y Lau; Jane Koh; Frankie K F Mo; Simon C H Yu; Anthony T Chan; Pun Hui; Brigette Ma; Kwok C Lam; Wing M Ho; Herman T Wong; Amanda Tang; Philip J Johnson
Journal:  J Natl Cancer Inst       Date:  2005-10-19       Impact factor: 13.506

9.  Prognosis of hepatocellular carcinoma: the BCLC staging classification.

Authors:  J M Llovet; C Brú; J Bruix
Journal:  Semin Liver Dis       Date:  1999       Impact factor: 6.115

10.  Claudin-3 and claudin-4 expression in ovarian epithelial cells enhances invasion and is associated with increased matrix metalloproteinase-2 activity.

Authors:  Rachana Agarwal; Theresa D'Souza; Patrice J Morin
Journal:  Cancer Res       Date:  2005-08-15       Impact factor: 12.701

View more
  163 in total

1.  The cellular protein lyric interacts with HIV-1 Gag.

Authors:  Christine E Engeland; Heike Oberwinkler; Michael Schümann; Eberhard Krause; Gerd A Müller; Hans-Georg Kräusslich
Journal:  J Virol       Date:  2011-09-28       Impact factor: 5.103

2.  Knockdown of Astrocyte Elevated Gene-1 Inhibits Activation of Hepatic Stellate Cells.

Authors:  Lei Chen; Yong-Ze Guo; Ai-di Li; Jun-Ji Ma; Hui-Yao Hao; Di Zhang; Yan Wang; Chen-Guang Ji; Wei Qi; Jia Wang; Hui-Qing Jiang
Journal:  Dig Dis Sci       Date:  2016-02-15       Impact factor: 3.199

Review 3.  AEG-1/MTDH/LYRIC in liver cancer.

Authors:  Devanand Sarkar
Journal:  Adv Cancer Res       Date:  2013       Impact factor: 6.242

Review 4.  The role of AEG-1/MTDH/LYRIC in the pathogenesis of central nervous system disease.

Authors:  Evan K Noch; Kamel Khalili
Journal:  Adv Cancer Res       Date:  2013       Impact factor: 6.242

5.  AU-binding factor 1 expression was correlated with metadherin expression and progression of hepatocellular carcinoma.

Authors:  Yingzhuo Yang; Peng Kang; Jie Gao; Chunlin Xu; Shimei Wang; Haiyu Jin; Yunling Li; Wenjuan Liu; Xia Wu
Journal:  Tumour Biol       Date:  2013-11-09

6.  Metadherin contribute to BCR signaling in chronic lymphocytic leukemia.

Authors:  Pei-Pei Li; Qing-Min Yao; Hui Zhou; Li-Li Feng; Xue-Ling Ge; Xiao Lv; Na Chen; Kang Lu; Xin Wang
Journal:  Int J Clin Exp Pathol       Date:  2014-03-15

7.  A novel role of astrocyte elevated gene-1 (AEG-1) in regulating nonalcoholic steatohepatitis (NASH).

Authors:  Jyoti Srivastava; Chadia L Robertson; Kareem Ebeid; Mikhail Dozmorov; Devaraja Rajasekaran; Rachel Mendoza; Ayesha Siddiq; Maaged A Akiel; Nidhi Jariwala; Xue-Ning Shen; Jolene J Windle; Mark A Subler; Nitai D Mukhopadhyay; Shah Giashuddin; Shobha Ghosh; Zhao Lai; Yidong Chen; Paul B Fisher; Aliasger K Salem; Arun J Sanyal; Devanand Sarkar
Journal:  Hepatology       Date:  2017-06-30       Impact factor: 17.425

Review 8.  Astrocyte elevated gene-1: far more than just a gene regulated in astrocytes.

Authors:  Devanand Sarkar; Luni Emdad; Seok-Geun Lee; Byoung Kwon Yoo; Zao-Zhong Su; Paul B Fisher
Journal:  Cancer Res       Date:  2009-11-10       Impact factor: 12.701

9.  Serum anti-AEG-1 auto-antibody is a potential novel biomarker for malignant tumors.

Authors:  Xi Chen; Ke Dong; Min Long; Fang Lin; Xi Wang; Junxia Wei; Jihong Ren; Huizhong Zhang
Journal:  Oncol Lett       Date:  2012-05-25       Impact factor: 2.967

10.  Astrocyte elevated gene-1: a novel target for human glioma therapy.

Authors:  Luni Emdad; Devanand Sarkar; Seok-Geun Lee; Zhao Zhong Su; Byoung Kwon Yoo; Rupesh Dash; Adly Yacoub; Christine E Fuller; Khalid Shah; Paul Dent; Jeffrey N Bruce; Paul B Fisher
Journal:  Mol Cancer Ther       Date:  2010-01-06       Impact factor: 6.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.